The BRCA trial

The BRCA trial is the world’s first international treatment trial investigating hereditary breast cancer. The trial was launched in May 2006. In the UK, the study is now part of the Triple Negative Trial.

The trial is still open to recruitment in Europe. For more information, please contact BRCA@ctc.ucl.ac.uk.

Trial Description

The BRCA trial is a phase II trial comparing the platinum-based chemotherapy drug, carboplatin, to the current recommended treatment, docetaxel. The study aims to determine whether carboplatin is a safe and potentially more effective treatment than docetaxel for breast cancers caused by the inheritance of faulty BRCA genes. Women in the study all have BRCA-associated breast cancer that has spread to other parts of the body.

Chief Investigator

Dr A Tutt
Breakthrough Breast Cancer Research Unit
King’s College London School of Medicine
Guy’s Hospital
London SE1 9RT

sora.vorapon@kcl.ac.uk